BR112016029635A2 - derivados pirazolo-piridina como inibidores de quinase - Google Patents

derivados pirazolo-piridina como inibidores de quinase

Info

Publication number
BR112016029635A2
BR112016029635A2 BR112016029635A BR112016029635A BR112016029635A2 BR 112016029635 A2 BR112016029635 A2 BR 112016029635A2 BR 112016029635 A BR112016029635 A BR 112016029635A BR 112016029635 A BR112016029635 A BR 112016029635A BR 112016029635 A2 BR112016029635 A2 BR 112016029635A2
Authority
BR
Brazil
Prior art keywords
kinase inhibitors
pyridine derivatives
pyrazolo pyridine
pyrazolo
diseases
Prior art date
Application number
BR112016029635A
Other languages
English (en)
Inventor
James Ford Daniel
Thomas Reuberson James
Original Assignee
Katholieke Univ Leuven K U Leuven R&D
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Univ Leuven K U Leuven R&D, Ucb Biopharma Sprl filed Critical Katholieke Univ Leuven K U Leuven R&D
Publication of BR112016029635A2 publication Critical patent/BR112016029635A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

é revelada uma série de derivados pirazolo[3,4-b]piridinas que são substituídas na posição 4 por um monocíclico diazo, em ponte bicíclico ou radical espirocíclico, sendo inibidores seletivos da atividade de fosfatidilinositol-4-quinase iiiß (pi4kiiiß), e são benéficos no tratamento e/ou prevenção de várias doenças humanas, incluindo distúrbios inflamatórios, auto-imunes e oncológicos, doenças virais e malária e em rejeição de transplante de células e órgãos.
BR112016029635A 2014-06-17 2015-06-11 derivados pirazolo-piridina como inibidores de quinase BR112016029635A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1410815.3A GB201410815D0 (en) 2014-06-17 2014-06-17 Therapeutic agents
PCT/EP2015/063048 WO2015193167A1 (en) 2014-06-17 2015-06-11 Pyrazolo-pyridine derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112016029635A2 true BR112016029635A2 (pt) 2017-08-22

Family

ID=51266751

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016029635A BR112016029635A2 (pt) 2014-06-17 2015-06-11 derivados pirazolo-piridina como inibidores de quinase

Country Status (11)

Country Link
US (1) US10087180B2 (pt)
EP (1) EP3157922B1 (pt)
JP (1) JP6602856B2 (pt)
CN (1) CN106459046B (pt)
BR (1) BR112016029635A2 (pt)
CA (1) CA2951419A1 (pt)
ES (1) ES2713403T3 (pt)
GB (1) GB201410815D0 (pt)
RU (1) RU2733400C2 (pt)
TR (1) TR201901338T4 (pt)
WO (1) WO2015193167A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201517263D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
GB201521767D0 (en) 2015-12-10 2016-01-27 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D Therapeutic agents
KR102523513B1 (ko) 2018-01-17 2023-04-18 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Pi4kiii베타 억제제
CN112752761B (zh) 2018-08-21 2024-03-29 杏林制药株式会社 双环杂芳族环衍生物
US11578071B2 (en) 2019-10-04 2023-02-14 University Of Kentucky Research Foundation Preparation of pyrazolo[3,4-B]pyridines as antimalarials
MX2023003995A (es) 2020-10-05 2023-06-12 Enliven Inc Compuestos de 5-y 6-azaindol para la inhibicion de tirosina cinasas bcr-abl.
CN113603639B (zh) * 2021-09-07 2023-06-27 黑龙江立科新材料有限公司 2-氰基-5-溴吡啶的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106635A1 (en) 2001-03-29 2004-06-03 Iwao Takamuro Spiroisoquinoline compound, a method for preparing the same and an intermediate thereof
JP2003252871A (ja) * 2001-03-29 2003-09-10 Tanabe Seiyaku Co Ltd スピロイソキノリン誘導体、その製法およびその合成中間体
RU2357967C2 (ru) * 2002-09-16 2009-06-10 Глаксо Груп Лимитед ПРОИЗВОДНЫЕ ПИРАЗОЛО[3, 4-b]ПИРИДИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ), ПРИМЕНЕНИЕ (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ)
JP2006056883A (ja) * 2004-07-23 2006-03-02 Tanabe Seiyaku Co Ltd 含窒素縮合二環式化合物およびその製法
WO2006009245A1 (ja) 2004-07-23 2006-01-26 Tanabe Seiyaku Co., Ltd. 含窒素縮合二環式化合物
PL1899333T3 (pl) * 2005-06-27 2009-07-31 Sanofi Aventis Pochodne pirazolopirydyny jako inhibitory kinazy 1 receptora beta-adrenergicznego
CA2711741A1 (en) * 2008-01-09 2009-07-16 Array Biopharma Inc. Pyrazolopyridines as kinase inhibitors
HUE034347T2 (en) * 2010-09-29 2018-02-28 Intervet Int Bv N-heteroaryl compounds with a cyclic bridge unit for the treatment of parasitic diseases
GB201115665D0 (en) * 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy
AU2013366480B2 (en) 2012-12-20 2017-06-22 Katholieke Universiteit Leuven, K.U.Leuven R&D Therapeutically active pyrazolo-pyrimidine derivatives

Also Published As

Publication number Publication date
CA2951419A1 (en) 2015-12-23
CN106459046B (zh) 2019-01-08
US10087180B2 (en) 2018-10-02
JP6602856B2 (ja) 2019-11-06
ES2713403T3 (es) 2019-05-21
GB201410815D0 (en) 2014-07-30
EP3157922B1 (en) 2018-11-28
CN106459046A (zh) 2017-02-22
RU2017101325A3 (pt) 2019-01-17
JP2017518383A (ja) 2017-07-06
RU2017101325A (ru) 2018-07-20
TR201901338T4 (tr) 2019-02-21
WO2015193167A1 (en) 2015-12-23
US20170121324A1 (en) 2017-05-04
EP3157922A1 (en) 2017-04-26
RU2733400C2 (ru) 2020-10-01

Similar Documents

Publication Publication Date Title
BR112016029635A2 (pt) derivados pirazolo-piridina como inibidores de quinase
BR112016011794A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112016011792A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112016012243A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112016029630A2 (pt) derivados heteroaromáticos bicíclicos fundidos como inibidores de inibidores de cinase
BR112016016158A2 (pt) Derivados de heterociclila bicíclicos como inibidores de irak4, sua composição farmacêutica e seus usos
BR112016029632A2 (pt) derivados heteroaromáticos bicíclicos fundidos como inibidores de cinase
BR112016011484A2 (pt) Derivados de imidazopirimidina como moduladores de atividade de tnf
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
BR112016012990A2 (pt) Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf
MY182454A (en) Dihydropyrrolopyridine inhibitors of ror-gamma
BR112016012242A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
CO7081142A2 (es) Métodos de tratamiento de enfermedades de degeneración retiniana
BR112016011483A2 (pt) Derivados de imidazotriazina como moduladores de atividade de tnf
BR112018006135A2 (pt) derivados de pirazol fundidos como inibidores da cinase
BR112016011527A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112016011485A2 (pt) Derivados de imidazopiridazina como moduladores de atividade de tnf
BR112016012258A2 (pt) Derivados de tetra-hidrobenzimidazol como moduladores de atividade de tnf
BR112016012261A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
TN2015000285A1 (en) Therapeutically active pyrazolo-pyrimidine derivatives
CL2015002620A1 (es) Derivados piridin-4-ilo
BR112016027691A2 (pt) Composto de tetra-hidropiridopirimidina e seus usos
HK1247923A1 (zh) 可用作哺乳動物酪氨酸激酶ror1活性抑制劑的2-苯基-3h-咪唑並[4，5-b]吡啶衍生物
ZA201701214B (en) Imidazo[1,2-a]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication
BR112016012254A2 (pt) Derivados de triazolpiridazina como moduladores de atividade de tnf

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2726 DE 04-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.